Other than ibrutinib, individuals with M-CLL, devoid of TP53 aberrations and fit more than enough to tolerate FCR therapy, should be very good candidates to the latter, Using the benefit remaining that this therapy is usually accomplished in 6 months even though ibrutinib has to be taken indefinitel